Nkarta, Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Nkarta, Inc. (NKTX) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $41.60 million as of 2020-07-01, per its 10-K filed 2022-03-17.
Discontinued › Notes › Fair Value Measures and Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2022-03-17
- 2020-07-01: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $41.60M.
- 2020-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $41.64M.
- 2019-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $1.48M; Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed $1.48M.
- 2019-08-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $2.80M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2020-07-01 | $41.60M 10-K · filed 2022-03-17 | |
| 2020-06-30 | $41.64M 10-Q · filed 2020-08-20 | |
| 2019-12-31 | $1.48M 10-K · filed 2022-03-17 | $1.48M 10-Q · filed 2020-08-20 |
| 2019-08-31 | $2.80M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |